Uncategorized
DDII UK Conference announces new panels on clinical trial design and early-stage funding
The Drug Discovery Innovators & Investors (DDII) UK Conference will take place at etc.venues Monument, London, on Wednesday 4 November. The conference brings together R&D leaders, lab managers, decision-makers from pharma and biotech companies, industry suppliers, researchers, start-ups, and investors to discuss key challenges in UK drug development.
Two new panels have been confirmed for the day.
Get It Done: Designing Faster, More Effective UK Clinical Trials will examine how technology, policy and infrastructure are enabling better clinical trials in the UK. Panellists will discuss the current strengths, barriers and opportunities for companies conducting clinical trials in the UK. Speakers include Janet Hemingway (Professor, Liverpool School of Tropical Medicine) and Philippa Brown (Head of Development Operations, GSK), with additional speakers to be announced.
Where Is the Money? Funding Early-Stage UK Drug Development in a Difficult Market will take an honest look at where early-stage capital is actually flowing in the UK, and what founders can do when venture capital isn’t an option. The panel brings together Sam Goldsmith (Head of Venture Creation, Cell and Gene Therapy Catapult), Ayokunmi Ajetunmobi (Head of Ventures, Pioneer Group) and Tanya Moore (Investment Principal, Cancer Research Horizons’ Ventures team).
As announced previously, Chris Molloy, CEO of the UK BioIndustry Association, will deliver the conference keynote.
The full-day conference will also feature interactive breakout workshops on topics such as AI in drug discovery, lab automation, spatial biology, and cell and gene therapy.
The programme features structured networking breaks to facilitate meaningful connections. Through the conference app, attendees can review delegate profiles and schedule 1:1 meetings in advance. This approach helps you connect with investors, buyers, collaborators, or clinical trial partners from the start, maximising your time and minimising reliance on chance meetings.
Early bird registration rates are available until 30 September 2026.
The post DDII UK Conference announces new panels on clinical trial design and early-stage funding appeared first on Drug Discovery World (DDW).
Uncategorized
STAT+: Pharmalittle: We’re reading about Replimune’s melanoma drug, a Medicare policy change, and more
And so, another working week will soon come to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is still taking shape, but we plan on promenading with the official mascots, catching up on our reading, escorting Mrs. Pharmalot to a speakeasy and, if time permits, holding another listening party, where the rotation will likely feature this, this, this, this and this. And what about you? Once again, we will remind you that the great outdoors is beckoning. With this in mind, time to grab your beach gear or strap on your hiking boots. If the weather fails to cooperate, you could always stroll around a museum, check out the new arrivals at your local library or curl up in front of the telly. Or maybe this is an opportunity to sit on the phone and reach out to a few special people. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon…
The U.S. Food and Drug Administration cleared Replimune’s treatment for advanced melanoma, dealing the biotech a major win after a tumultuous saga of trying to seek approval for the controversial treatment, STAT notes. The decision to grant accelerated approval to the drug, which will be marketed as Tudriqev, came after its FDA advisers last week voted in support of the treatment. Even though FDA staff expressed concerns about the design and conduct of the key trial, advisers ultimately believed there was a large enough signal of efficacy and that patients are in urgent need of new treatments.
A little-noticed policy shift by Medicare caused a seven-year delay in choosing a costly AbbVie medicine for price negotiations, a move likely to hurt taxpayers, STAT writes, citing an analysis by a consumer advocacy group. The change occurred as the Centers for Medicare and Medicaid Services readied a new round of talks with drugmakers over prices the agency would pay for a limited number of drugs. The process was created by the Inflation Reduction Act. But CMS modified criteria for selecting drugs for the negotiations, which transformed the process for determining when certain medicines would become eligible for the talks. And it was done in a way that benefited AbbVie and may help other drugmakers in the future.
And so, another working week will soon come to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is still taking shape, but we plan on promenading with the official mascots, catching up on our reading, escorting Mrs. Pharmalot to a speakeasy and, if time permits, holding another listening party, where the rotation will likely feature this, this, this, this and this. And what about you? Once again, we will remind you that the great outdoors is beckoning. With this in mind, time to grab your beach gear or strap on your hiking boots. If the weather fails to cooperate, you could always stroll around a museum, check out the new arrivals at your local library or curl up in front of the telly. Or maybe this is an opportunity to sit on the phone and reach out to a few special people. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon…
The U.S. Food and Drug Administration cleared Replimune’s treatment for advanced melanoma, dealing the biotech a major win after a tumultuous saga of trying to seek approval for the controversial treatment, STAT notes. The decision to grant accelerated approval to the drug, which will be marketed as Tudriqev, came after its FDA advisers last week voted in support of the treatment. Even though FDA staff expressed concerns about the design and conduct of the key trial, advisers ultimately believed there was a large enough signal of efficacy and that patients are in urgent need of new treatments.
A little-noticed policy shift by Medicare caused a seven-year delay in choosing a costly AbbVie medicine for price negotiations, a move likely to hurt taxpayers, STAT writes, citing an analysis by a consumer advocacy group. The change occurred as the Centers for Medicare and Medicaid Services readied a new round of talks with drugmakers over prices the agency would pay for a limited number of drugs. The process was created by the Inflation Reduction Act. But CMS modified criteria for selecting drugs for the negotiations, which transformed the process for determining when certain medicines would become eligible for the talks. And it was done in a way that benefited AbbVie and may help other drugmakers in the future.
Uncategorized
Is the biotech capital of the world moving?
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Boston’s biotech identity is under pressure as founders decamp for California, Alzheimer’s researchers uncover more secrets of tau function, and Replimune finally secures a hard-fought FDA approval.
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Boston’s biotech identity is under pressure as founders decamp for California, Alzheimer’s researchers uncover more secrets of tau function, and Replimune finally secures a hard-fought FDA approval.
Uncategorized
Intellia finds genetic suspect for liver safety signals with ATTR gene therapy
Intellia finds genetic suspect for liver safety signals with ATTR gene therapy
In November 2025, one patient died after receiving Intellia Therapeutics’ investigational gene silencer for transthyretin amyloidosis. Read More
Illinois’ financial crisis could bring the state to a halt
The final 6 ‘Game of Thrones’ episodes might feel like a full season
New Season 8 Walking Dead trailer flashes forward in time
Mod turns ‘Counter-Strike’ into a ‘Tekken’ clone with fighting chickens
Meet Superman’s grandfather in new trailer for Krypton
Disney’s live-action Aladdin finally finds its stars
STAT+: Pharmalittle: We’re reading about Replimune’s melanoma drug, a Medicare policy change, and more
Is the biotech capital of the world moving?
Intellia finds genetic suspect for liver safety signals with ATTR gene therapy
Vistagen’s repeat-dose anxiety nasal spray can’t beat placebo in mid-stage study
STAT+: He grew up near Boston, went to Harvard, and worked at MIT. Why did he found his startup in California?
Opinion: AI won’t enhance physician autonomy. It will further diminish it
Illinois’ financial crisis could bring the state to a halt
The final 6 ‘Game of Thrones’ episodes might feel like a full season
New Season 8 Walking Dead trailer flashes forward in time
Mod turns ‘Counter-Strike’ into a ‘Tekken’ clone with fighting chickens
Meet Superman’s grandfather in new trailer for Krypton
Disney’s live-action Aladdin finally finds its stars
-
Fierce Biotech4 months ago
Scientists turn pig semen extract into eye drops that kill cancer in mice
-
Uncategorized9 years agoThese ’90s fashion trends are making a comeback in 2017
-
Endpoints News5 months ago
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
-
Uncategorized5 months agoNovartis buys Synnovation’s PI3Kα inhibitors for $3 billion
-
Uncategorized9 years ago
According to Dior Couture, this taboo fashion accessory is back
-
Uncategorized9 years ago
Steph Curry finally got the contract he deserves from the Warriors
-
Uncategorized9 years ago
Phillies’ Aaron Altherr makes mind-boggling barehanded play
-
Uncategorized9 years ago
Uber and Lyft are finally available in all of New York State